Full Breakdown
President Trump and the Mystery Access to Eli Lilly’s Experimental Obesity Drug Retatrutide
6/26/2026, 5:22:40 AM
Unusual Compassionate-Use Approval for Retatrutide
In April 2026 the U.S. Food and Drug Administration granted a single “compassionate-use” (expanded-access) approval for retatrutide, Eli Lilly’s experimental obesity therapy, to a 79-year-old patient diagnosed with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. The request was filed by NIH senior clinician Ranganath Muniyappa. Because the patient’s age matched President Donald Trump’s age at the time, media outlets speculated that the drug might have been given to the president.
Background: Retatrutide and the Compassionate-Use Pathway
Retatrutide is a next-generation GLP-1/GIP/glucagon agonist that has not yet received FDA approval. Phase 3 data released in May 2026 showed an average 28 % body-weight loss after 80 weeks—levels comparable to bariatric surgery. The FDA’s compassionate-use program is intended for patients with serious or immediately life-threatening conditions who lack comparable therapies; it is typically used for terminal illnesses rather than obesity.
Key Players
- Eli Lilly – developer of retatrutide.
- FDA – authorized the single compassionate-use case.
- Ranganath Muniyappa – NIH clinician who submitted the request.
- Unnamed 79-year-old patient – the sole recipient of the drug.
- White House – spokespersons Kush Desai (Deputy Press Secretary) and Steven Cheung (Communications Director) publicly denied the patient was the president.
- Congressional officials – Rep. Ted Lieu and other Democratic lawmakers pressed for clarification.
- Bioethics and obesity experts – voiced concerns about the appropriateness of the request.
Timeline
- April 2026 – Compassionate-use request submitted.
- June 23 2026 – STAT News reports the case; White House denies Trump involvement.
- June 24 2026 – Rep. Ted Lieu asks the administration for details at a press briefing.
- May 2026 – President Trump’s physical exam lists weight 238 lb and “excellent health.”
- Earlier 2026 – Trump purchased Eli Lilly stock and announced a federal deal to lower GLP-1 drug prices.
Data on Retatrutide
The drug targets three hormones (GLP-1, GIP, glucagon), making it more potent than earlier GLP-1 agents such as Wegovy or Ozempic. In the Phase 3 trial, participants without diabetes lost 28 % of body weight after 80 weeks. The mystery patient had previously taken tirzepatide for a year, achieving only moderate weight loss.
Why It Matters
The case raises ethical questions about using compassionate-use pathways for a non-life-threatening condition, potential preferential access for a high-profile individual, and a possible conflict of interest given the president’s recent Eli Lilly investment. It also spotlights the need for transparency in FDA-industry collaborations.
Official Statements & Responses
- White House (Kush Desai): Stated the application “was not for the President” and redirected inquiries to the Department of Health and Human Services.
- White House (Steven Cheung): Dismissed the reporting as “deranged” and attacked the journalist.
- Eli Lilly: Declined to comment on the individual case, noting compassionate-use is offered when patients cannot join a trial and have exhausted other options.
- Medical memo: The president’s health memo made no mention of obstructive sleep apnea or pulmonary hypertension.
Criticism & Opposition
Bioethics experts, including Jamy Ard (Advocate Health), emphasized that compassionate-use requests are “usually reserved for terminal illness.” More than a dozen obesity clinicians described the single-patient approval as “very unusual.” Democratic lawmakers, led by Rep. Ted Lieu, called for greater disclosure, arguing the pathway is meant for larger patient cohorts.
Conflicting Reports & Gaps
- No source confirmed the patient’s identity; STAT News and Snopes note other prominent 79-year-olds could fit the profile.
- The White House memo omits the conditions cited in the request.
- The exact date the patient began treatment and any observed weight-loss outcomes remain undisclosed.
Verbatim Quotes
- “Because this has to be spelled out for @LizzyLaw_, who has proven herself to be an unserious gossip columnist, this application was not for the President.” — Kush Desai, White House spokesperson
- “You thought this was your big shot, but in reality, you’re just a big idiot. You certainly made a name for yourself by completely embarrassing yourself at the expense of being thirsty for clicks and peddling falsehoods,” — Steven Cheung, White House communications director
- “President Trump remains in excellent health, demonstrating strong cardiac, pulmonary, neurological, and overall physical function,” — Dr. Sean Barbabella, White House physician
- “Often, drugmakers will establish compassionate use programs for large cohorts of patients,” — Unnamed bioethics expert cited by STAT
What’s Next
Congressional leaders have scheduled follow-up hearings to demand clarification of the compassionate-use decision. The FDA is expected to release the final results of the retatrutide Phase 3 trial in 2028, which may shape future policy on expanded-access use for obesity treatments.
